Objectives: Thyroid diseases and their treatment may influence the osseous system. The influence that prolonged suppressive L-thyroxine (LT4) therapy may have on inducing subclinical hyperthyroidism on bone metabolism is still a matter of debate. The aim of the present study was to assess the effects of chronic LT4 treatment at mildly inhibiting serum thyroid-stimulating hormone (TSH) doses on bone mineral density (BMD) and biochemical bone remodeling markers in a cohort of women with benign nodular goiter, and to verify the efficacy of the treatment on nodule size. Subjects and Study Design: A total of 200 euthyroid Caucasian women with nodular goiter (age 52.1 ± 9; 80 pre- and 120 postmenopausal) were enrolled: 96 had been treated with LT4 for at least 3 years and a matched group of 104 had untreated goiter. LT4 therapy was given at a dose sufficient to reduce TSH under the lower limit of the normal range (0.27–4.20 µIU/ml) without suppressing it below the limit of assay sensitivity (0.005 µIU/ml) and maintaining normal serum values of free triiodothyronine (FT3) and free thyroxine (FT4). The adequacy of the dose was evaluated on the basis of serum TSH levels. The osteopenic effect of LT4 treatment was evaluated directly by total body and lumbar spine dual-energy X-ray absorptiometry (DEXA) and indirectly by biochemical parameters (alkaline phosphatase, osteocalcin, calcium, parathyroid hormone) at the baseline and throughout the follow-up. The efficacy of LT4 schedule on thyroid nodule size was assessed on the basis of the ultrasonographic evaluation. Results: Mineralometric data showed no significant difference between BMD values for treated and untreated patients in both pre- and postmenopausal status. In all patients, serum markers of bone turnover were in the normal range, with no differences in the treated and control groups. The TSH concentrations were significantly lower in treated than in untreated patients (p < 0.0001); FT3 and FT4 were in the normal range for all patients. Evaluation of nodule size during follow-up showed a reduction of ≧30% in 32 of 96 treated patients (33.3%) versus none in those untreated, whilst nodule size remained unmodified in 60 treated patients (62.5%) versus 35 (33.6%) in those untreated, and an increase in nodule size and/or development of new nodules was found in 4 treated patients (4.2%) versus 69 of the 104 untreated patients (66.3%). Conclusions: This study suggests that at slightly suppressing TSH doses, LT4 therapy has no adverse effects on BMD in both pre- and postmenopausal women, while having an efficacy on nodule size comparable with that reported using an LT4 schedule able to maintain TSH near or below the assay sensitivity limit.

Keywords:
Benign nodular goiter, L-Thyroxine, Computerized bone mineralometry, Osteoporosis
1.
Ross DS, Neer RM, Ridgway EC, Daniels GH: Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1987;82:1167–1170.
2.
De Rosa G, Testa A, Giacomini D, Carrozza C, Astazi P, Caradonna P: Prospective study of bone loss in pre- and post-menopausal women on L-Thyroxine therapy for non toxic goitre. Clin Endocrinol (Oxf) 1997;47:529–535.
3.
Greenspan SL, Greenspan FS: The effect of thyroid hormone on skeletal integrity. Ann Intern Med 1999;130:750–758.
4.
Pantazi H, Papapetru PD: Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J Clin Endocrinol Metab 2000;88:1099–1106.
5.
Mikosch P, Jauk B, Gallowitsch HJ, Pipam W, Kresnik E, Lind P: Suppressive levothyroxine therapy has no significant influence on bone degradation in women with thyroid carcinoma: a comparison with other disorders affecting bone metabolism. Thyroid 2001;11:257–263.
6.
Vestergaard P, Rejnmark L, Weeke J, Mosekilde L: Fracture risk in patients treated for hyperthyroidism. Thyroid 2000;10:341–348.
7.
Hadji P, Ilars O, Sturm G, Bauer T, Amons G, Schultz K: The effect of long-term, non suppressive levothyroxine treatment on quantitative ultrasonometry of bone in women. Eur J Endocrinol 2000;142:445–450.
8.
Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchera A: Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 1994;78: 816–817.
9.
Guo CY, Weetman AP, Eastell R: Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol (Oxf) 1997;46:301–307.
10.
Kisakol G, Kaya A, Gonen S, Tunc R: Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J 2003;50:657–661.
11.
Lee MS, Kim SY, Loe MC, et al: Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism. J Clin Endocrinol Metab 1990;70:766–770.
12.
Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L, Siersback-Nielsen K: Normalization of serum thyrotropin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf) 1998;48:285–290.
13.
Foldes J, Tarjan G, Szathmari M, Varga F, Krasznai I, Horvath C: Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? Clin Endocrinol (Oxf) 1993;39:521–527.
14.
Gurlek A, Gedik O: Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 1999;9:539–543.
15.
De Rosa G, Testa A, Maussier ML, Calla C, Astazi P, Albanese C: A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre. Horm Metab Res 1995;27:503–507.
16.
Schindler AE: Thyroid function and postmenopause. Gynecol Endocrinol 2003;17:79–85.
17.
Sijanovic S, Karner I: Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone. Medscape Womens Health 2001;6:3.
18.
Ben-Shlomo A, Hagag P, Evans S, Weiss M: Early postmenopausal bone loss in hyperthyroidism. Maturitas 2001;39:19–27.
19.
Diamond T, Nery L, Hales Y: A therapeutic dilemma: suppressive doses of thyroxine reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 1990;72:1184–1188.
20.
Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B: Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 1990;113:265–269.
21.
Greenspan SL, Greenspan FS, Resnick NM, Block JE, Friedlander AI, Genant HK: Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy. Am J Med 1991;91:5–14.
22.
Leese GP, Jung RT, Guthrie C, Waugh N, Browing MCK: Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol (Oxf) 1992;37:500–504.
23.
De Menis E, Da Rio G, Roiter I, Legovini P, Foscolo G, Conte N: Bone turnover in overt and subclinical hyperthyroidism due to autonomous thyroid adenoma. Horm Res 1992;37:217–220.
24.
Sato K, Han DC, Fujii Y, Tsushima T, Shizume K: Thyroid hormone stimulates alkaline phosphatase activity in cultured rat osteoblastic cells (ROS 17/2.8) through 3,5,3′-triiodo-L-thyroxine nuclear receptors. Endocrinology 1987;120:1873–1881.
25.
Kisakol G, Kaya A, Gonen S, Tunc R: Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J 2003;50:657–661.
26.
Vestergaard P, Mosekilde L: Hyperthyroidism, bone mineral, and fracture risk. A meta-analysis. Thyroid 2003;13:585–593.
27.
Eriksen EF, Mosekilde L, Melsen F: Trabecular bone remodeling and bone balance in hyperthyroidism. Bone 1985;6:421–428.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.